*仅供医学专业人士阅读参考
特立氟胺治疗MS,EAN 2022提供了更多的充分依据,让临床医生手中的“武器”变得更加锋利。
MS阴燃病灶:平静水面下的暗流
近年来,越来越多的研究提示,MS患者即使未发生复发,脑内也可能存在阴燃病灶(smouldering disease),甚至阴燃病灶在疾病早期就已经发生[1]。图1生动的展示了具有阴燃病灶的MS患者的一些表现。
B细胞、小胶质细胞和BTK抑制剂
特立氟胺的中国声音
特立氟胺在特殊人群中的使用
专家点评
周红雨 教授
参考文献
[6]Melamed E, Lee MW. Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies. Front Immunol. 2020;10:2954. Published 2020 Jan 10.
[7]Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164-174.
[8]Komori M, Lin YC, Cortese I, et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol. 2016;3(3):166-179. Published 2016 Feb 1.
[9]Sierra A, Paolicelli RC, Kettenmann H. Cien Años de Microglía: Milestones in a Century of Microglial Research. Trends Neurosci. 2019;42(11):778-792.
[10]Guerrero BL, Sicotte NL. Microglia in Multiple Sclerosis: Friend or Foe?. Front Immunol. 2020;11:374. Published 2020 Mar 20.
[11]Liang C, Tian D, Ren X, et al. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem. 2018;151:315-326.
[12]Hendriks RW. Drug discovery: New Btk inhibitor holds promise. Nat Chem Biol. 2011;7(1):4-5.
[13]Miller AE, O’Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Multiple Sclerosis Journal. 2012;18(11):1625-1632.
[14]Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(3):247-256.
[15]Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology 2014;13(10):977-986.
[16]Vukusic S, Coyle PK, Jurgensen S, et al. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler. 2020;26(7):829-836.
[17]特立氟胺片说明书. 核准日期:2018年7月18日, 最新修改日期2022年1月26日.
[18]Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54-59.
[19]Chitnis T, Banwell B, Kappos L, et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(12):1001-1011.
[20]https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio
[21]https://www.globenewswire.com/news-release/2021/06/18/2249701/0/en/European-Commission-approves-Aubagio-teriflunomide-as-the-first-oral-MS-therapy-for-first-line-treatment-of-children-and-adolescents-living-with-relapsing-remitting-multiple-sclero.html
[MAT-CN-2213634,有效期至2024年7月12日]本编号仅作为赛诺菲对本文章所涉及的赛诺菲相关药物所属治疗领域科学和临床数据来源真实性的确认,不作为赛诺菲对本文章全部内容准确性、时效性和完整性的确认和保证;本文章仅供医疗卫生专业人士为学术交流或了解医学资讯目的使用,不构成对任何药物或治疗方案的推荐和推广。本文章所含信息不应代替医疗卫生专业人士提供的医疗建议。
联系客服